Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BD Gets EUA for At-Home Covid-19 Test That Uses Smartphone

08/25/2021 | 03:34pm EDT

By Stephen Nakrosis

Becton, Dickinson and Co. on Wednesday said the U.S. Food and Drug Administration issued an emergency use authorization for the company's Veritor At-Home Covid-19 Test, which allows users to use a smartphone to interpret and display results.

The company said users can complete the nasal-swab test in the privacy of their homes and use the camera on their smartphone to "capture, analyze and interpret the results, which eliminates the human subjectivity of a visually read test."

The mobile app from Scanwell Health is available on iOS and Android and provides step-by-step instructions, BD said.

Dave Hickey, president of Life Sciences for BD, said, "New mandates from governments and businesses are specifying the need for periodic testing for those who cannot or chose not to be vaccinated, and this new test may help businesses, governments or schools fulfill those requirements."

The test can be used by people 14 and older, and can also be used on children as young as 2 with samples collected by an adult, the company said.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

08-25-21 1734ET

All news about BECTON, DICKINSON AND COMPANY
10/22BECTON DICKINSON & CO : Change in Directors or Principal Officers (form 8-K)
AQ
10/22Becton, Dickinson and Company Names Dr. Carrie Byington To Board Of Directors
CI
10/19BECTON DICKINSON AND : BD Launches New 'Together We Advance' Environmental, Social, Govern..
AQ
10/18Becton, Dickinson Unveils ESG Strategy for 2030
DJ
10/18BECTON DICKINSON AND : BD Launches New 'Together We Advance' Environmental, Social, Govern..
PR
10/13BECTON DICKINSON AND : BD Launches Plunger Stopper in Partnership with Aptar Pharma to Enh..
PU
10/07BECTON DICKINSON AND : Expands Capacity at Manufacturing Facility in Nebraska
MT
10/07BECTON DICKINSON AND : BD Announces 510(k) Clearance of Expanded Indications for the Rotar..
AQ
10/07BECTON DICKINSON AND : BD Unveils Nebraska-Based Manufacturing Capacity to Support U.S. Va..
PR
10/06BECTON DICKINSON AND : Receives FDA Clearance of Expanded Indications for Rotarex Atherect..
MT
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2021 20 006 M - -
Net income 2021 2 231 M - -
Net Debt 2021 14 859 M - -
P/E ratio 2021 32,1x
Yield 2021 1,49%
Capitalization 70 962 M 70 962 M -
EV / Sales 2021 4,29x
EV / Sales 2022 4,31x
Nbr of Employees 72 000
Free-Float 78,2%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 247,09 $
Average target price 270,20 $
Spread / Average Target 9,35%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Chris DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY-1.25%70 962
ABBOTT LABORATORIES15.74%224 651
MEDTRONIC PLC5.08%165 656
HOYA CORPORATION21.65%56 316
DEXCOM, INC.53.24%54 815
SARTORIUS STEDIM BIOTECH64.49%51 360